Pharmaceutical company intelligence

Reign Pharmaceuticals PCSIR - KLC (Pvt.) Ltd.

Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.

Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view

Rx47product presentations

G22generic molecules

DF6dosage-form groups

TA2therapeutic areas

PKR47current price records

REG40registration numbers

Data coverage

How complete is this profile?

Current price coverage100%

products with a current official price

Source-linked coverage100%

products linked back to a source record

Unit-price parse coverage100%

priced packs safely normalized per unit

Comparable-market coverage94%

products with at least one like-for-like comparator

Portfolio intelligence

Therapeutic mix

Unclassified43 products · 91%

Fluoroquinolone antibacterials2 products · 4%

Third-generation cephalosporins2 products · 4%

Formulation footprint

Dosage forms

Tablet21 products

Suspension10 products

Injection5 products

Capsule4 products

Syrup4 products

Sachet3 products

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales

#1 RenfloxCiprofloxacin 5presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Tablet #2 NuprinIbuprofen 3presentations 100 mg/5 mL · Suspension #3 REFTOXCefotaxime 3presentations 1 g, 250 mg, 500 mg · Injection #4 RenzithAzithromycin 3presentations 200 mg/5 mL, 250 mg, 500 mg · Suspension, Tablet #5 AndinLoratadine 2presentations 10 mg, 5 mg/5 mL · Tablet, Syrup #6 DumolParacetamol 2presentations 120 mg/5 mL · Syrup

Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis

Below market median1227% of comparable products

Near market median28within ±5% of median

Above market median49% of comparable products

Lowest-price equivalents2ties included

Company median price position -0.1% relative to the median unit price of like-for-like equivalent products.

Most competitively positioned examplesProducts with at least 3 market comparators

Rentanic 150 mg + 0.5 mgFerrous sulfate + Folic acid · Tablet · 1000's PKR 0.95/tablet-40.1% vs market median Renflu 150 mgFluconazole · Tablet · 1's PKR 130.21/tablet-29.3% vs market median Rezo-lid 400 mgLinezolid · Tablet · 12's PKR 176.03/tablet-23.9% vs market median Renflox 250 mg/5 mLCiprofloxacin · Dry suspension · 120ml PKR 3.80/mL-22.9% vs market median Andin 10 mgLoratadine · Tablet · 10's PKR 10.83/tablet-22.6% vs market median

How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Semos Pharmaceuticals PVT LTD103 products · 45 generics 19shared generics Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 18shared generics Bosch Pharmaceuticals (Pvt) Ltd.250 products · 73 generics 17shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 17shared generics Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 16shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.239 products · 98 generics 16shared generics

Regulatory & price activity

Observed database signals

Registration numbers40

Price-history records54

Products with price history6

Source records with multiple versions0

Latest MedInfoBase verification9 Aug 2026

Latest effective price date1 Jul 2025

Latest source observation9 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed

Complete company portfolio

Products and presentations

47 results

Brand	Generic	Strength	Form	Pack	Registration	Official price	Unit price	Market position
Andin	Loratadine	10 mg	Tablet	10's	100088	PKR 108.25	PKR 10.83/tablet	23% below median
Andin	Loratadine	5 mg/5 mL	Syrup	60ml	100089	PKR 84.96	PKR 1.42/mL	15% below median
C-Throcin	Clarithromycin	125 mg/5 mL	Dry suspension	60ml	073800	PKR 423.88	PKR 7.06/mL	Near median
Dumol	Paracetamol	120 mg/5 mL	Syrup	60ml	076476	PKR 62.91	PKR 1.05/mL	Near median
Dumol	Paracetamol	120 mg/5 mL	Syrup	100ml	076476	PKR 102.63	PKR 1.03/mL	Near median
Folic Acid	Folic acid	5 mg	Tablet	100's	086769	PKR 79.94	PKR 0.80/tablet	Near median
Gnate	Artemether + Lumefantrine	40 mg + 240 mg	Tablet	8's	073794	PKR 501.81	PKR 62.73/tablet	Near median
Gnate	Artemether + Lumefantrine	40 mg + 240 mg	Tablet	10's	073794	PKR 589.25	PKR 58.93/tablet	8% below median
Gnate DS	Artemether + Lumefantrine	80 mg + 480 mg	Tablet	4's	073795	PKR 418.17	PKR 104.54/tablet	Near median
Largimox	Moxifloxacin	400 mg	Tablet	5's	073791	PKR 902.88	PKR 180.58/tablet	Near median
Lesil	Levofloxacin	500 mg	Tablet	10's	073793	PKR 790.73	PKR 79.07/tablet	Near median
Lesil	Levofloxacin	250 mg	Tablet	10's	097117	PKR 475.20	PKR 47.52/tablet	Near median
Loczole	Fluconazole	150 mg	Capsule	1's	073797	PKR 262.32	PKR 262.32/capsule	Near median
Nuprin	Ibuprofen	100 mg/5 mL	Suspension	60ml	076477	PKR 64.01	PKR 1.07/mL	13% above median
Nuprin	Ibuprofen	100 mg/5 mL	Suspension	90ml	076477	PKR 96.01	PKR 1.07/mL	13% above median
Nuprin	Ibuprofen	100 mg/5 mL	Suspension	120ml	076477	PKR 129.12	PKR 1.08/mL	14% above median
OM-R	Omeprazole enteric coated pellets	40 mg	Capsule	14's	076745	PKR 475.20	PKR 33.94/capsule	Near median
OM-R	Omeprazole enteric coated pellets	20 mg	Capsule	14's	076746	PKR 273.70	PKR 19.55/capsule	Near median
RAYFIX	Cefixime	100 mg/5 mL	Suspension	30ml	088953	PKR 285.13	PKR 9.50/mL	9% below median
RAYFIX	Cefixime	400 mg	Capsule	5's	088954	PKR 564.16	PKR 112.83/capsule	Near median

MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.